MA50074A - Dérivés d'analogues de tyrosine en tant qu'inhibiteurs de rho-kinase - Google Patents

Dérivés d'analogues de tyrosine en tant qu'inhibiteurs de rho-kinase

Info

Publication number
MA50074A
MA50074A MA050074A MA50074A MA50074A MA 50074 A MA50074 A MA 50074A MA 050074 A MA050074 A MA 050074A MA 50074 A MA50074 A MA 50074A MA 50074 A MA50074 A MA 50074A
Authority
MA
Morocco
Prior art keywords
rho
kinase inhibitors
tyrosine analogues
analogues
tyrosine
Prior art date
Application number
MA050074A
Other languages
English (en)
Inventor
Alessandro Accetta
Gurdip Bhalay
Anna Maria Capelli
Arnaud Jean Francois Auguste Cheguillaume
Christine Edwards
Fabio Rancati
Patrizia Tisselli
Original Assignee
Chiesi Farm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farm Spa filed Critical Chiesi Farm Spa
Publication of MA50074A publication Critical patent/MA50074A/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995Pyrazines or piperazines forming part of bridged ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA050074A 2017-09-07 2018-09-05 Dérivés d'analogues de tyrosine en tant qu'inhibiteurs de rho-kinase MA50074A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17189933 2017-09-07

Publications (1)

Publication Number Publication Date
MA50074A true MA50074A (fr) 2021-04-28

Family

ID=59858880

Family Applications (1)

Application Number Title Priority Date Filing Date
MA050074A MA50074A (fr) 2017-09-07 2018-09-05 Dérivés d'analogues de tyrosine en tant qu'inhibiteurs de rho-kinase

Country Status (4)

Country Link
US (1) US11147812B2 (fr)
EP (1) EP3679039B1 (fr)
MA (1) MA50074A (fr)
WO (1) WO2019048479A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES3041795T3 (en) 2020-12-15 2025-11-14 Chiesi Farm Spa Dihydrofuropyridine derivatives as rho- kinase inhibitors
JP2023552901A (ja) 2020-12-15 2023-12-19 キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ Rhoキナーゼ阻害剤としてのジヒドロフロピリジン誘導体
WO2022128853A1 (fr) 2020-12-15 2022-06-23 Chiesi Farmaceutici S.P.A. Dérivés de dihydrofuropyridine utilisés comme inhibiteurs de la rho kinase
WO2023110700A1 (fr) 2021-12-13 2023-06-22 Chiesi Farmaceutici S.P.A. Dérivés de dihydrofuropyridine utilisés comme inhibiteurs de la rho-kinase

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2273047T3 (es) 2002-10-28 2007-05-01 Bayer Healthcare Ag Fenilaminopirimidinas sustituidas con heteroariloxi como inhibidores de rho-cinasa.
DE102004017438A1 (de) * 2004-04-08 2005-11-03 Bayer Healthcare Ag Hetaryloxy-substituierte Phenylaminopyrimidine
WO2006009889A1 (fr) 2004-06-17 2006-01-26 Smithkline Beecham Corporation Inhibiteurs novateurs de protéines rho-kinases
WO2009079008A1 (fr) 2007-12-19 2009-06-25 Yangbo Feng Benzopyranes et analogues utilisés comme inhibiteurs de la rho kinase
MX2011002825A (es) 2008-09-18 2011-04-05 Astellas Pharma Inc Compuestos heterociclicos de carboxamida.
EP2593452B1 (fr) 2010-07-14 2017-01-18 Novartis AG Composés hétérocycliques agonistes du récepteur ip
PT2951172T (pt) 2013-01-29 2017-07-12 Redx Pharma Plc Derivados de piridina como inibidores de rock leves
ES2866152T3 (es) * 2017-01-30 2021-10-19 Chiesi Farm Spa Derivados de tirosina amida como inhibidores de la Rho-quinasa

Also Published As

Publication number Publication date
EP3679039A1 (fr) 2020-07-15
EP3679039B1 (fr) 2021-06-16
WO2019048479A1 (fr) 2019-03-14
US11147812B2 (en) 2021-10-19
US20210023080A1 (en) 2021-01-28

Similar Documents

Publication Publication Date Title
MA47460A (fr) Aminotriazolopyridines utilisées en tant qu'inhibiteurs de kinase
MA48994A (fr) Isoquinoléines utilisées en tant qu'inhibiteurs de hpk1
MA52486A (fr) Pyridazinones utilisés en tant qu'inhibiteurs de parp7
MA45244A (fr) Pyridines substituées utilisées en tant qu'inhibiteurs de dnmt1
MA46339A (fr) Dérivés de cyanopyrrolidine ayant une activité en tant qu'inhibiteurs de l'usp 30
EP3416964A4 (fr) Dérivés de carboxamide utiles en tant qu'inhibiteurs de rsk
EP3687543A4 (fr) Agents pharmaceutiques en combinaison en tant qu'inhibiteurs de rsv
MA47123A (fr) Dérivés de benzooxazole en tant qu'mmunomodulateurs
MA47125A (fr) Dérivés de pyrazole en tant qu'inhibiteurs de malt1
MA53150A (fr) Composés de benzimidazole en tant qu'inhibiteurs de c-kit
MA47086A (fr) Dérivés de dihydropyrimidine-carboxamide bicycliques utilisés en tant qu'inhibiteurs de rho-kinase
MA46981A (fr) Dérivés de benzimidazole en tant qu'inhibiteurs de bromodomaine
MA42659A (fr) Dérivés hétéroaryle utilisés en tant qu'inhibiteurs de parp
MA43862A (fr) Spiroheptane salicylamides et composés associés en tant qu' inhibiteurs de rock
MA40774A (fr) Dérivés de diaryle-urée en tant qu'inhibiteurs de kinase p38
MA45153A (fr) Dérivés de carbonucléosides substitués utiles en tant qu'agents anticancéreux
EP3464275A4 (fr) Composés inhibiteurs de l'egfr
MA47013A (fr) Composés benzolactames utilisés en tant qu'inhibiteurs de protéine kinase
MA41140A (fr) Dérivés de 2,4-dioxo-quinazoline-6-sulfonamide en tant qu'inhibiteurs de la parg
MA52123A (fr) Dérivé de 6-pyrimidine-isoindole utilisé en tant qu'inhibiteur de erk1/2
MA48803A (fr) Cycles 6-5 fusionnés utilisés en tant qu'inhibiteurs de c5a
EP3733671A4 (fr) Dérivés amino-fluoropipéridines utilisés en tant qu'inhibiteur de kinase
MA46745A (fr) Dérivés d'indazole en tant qu'antagonistes de l'intégrine alpha v
MA50013A (fr) Analogues de benzoazépine utilisés en tant qu'agents inhibiteurs de la tyrosine kinase de bruton
MA46878A (fr) Composés de benzodiazolium en tant qu'inhibiteurs d'enac